1. Market Research
  2. > Pharmaceutical
  3. > Pathology Market Trends
  4. > EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024

EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024

Summary

Non-Hodgkin’s Lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the body’s immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the body’s inability to fight infections and other diseases. NHL is characterized into three types - B-cell, T-cell, and natural killer lymphocyte lymphomas. This epidemiological analysis focuses specifically on four subtypes of B-cell NHL: follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma. NHL is more common in men than in women, in white men and women compared with black men and women, and the incidence exponentially increases with age.

GlobalData epidemiologists forecast an increase in the incident cases of the four B-cell NHL in the 7MM, from 104,854 incident cases in 2014 to 129,179 incident cases in 2024, with an annual growth rate (AGR) of 2.32%. Throughout the forecast period, the US will have the highest number of incident cases of B-cell NHL, as well as 36% growth during the forecast period, ending with 57,724 incident cases in 2024. Additionally, each of the 7MM will see an increase in incident cases over the 10-year forecast period.

For this analysis, GlobalData epidemiologists utilized peer-reviewed journals and country-specific disease databases to construct the 10-year epidemiological forecast for the incident cases of follicular lymphoma, marginal zone lymphoma, DLBCL, and mantle cell lymphoma in the 7MM. A major strength of GlobalData’s epidemiological analysis is the exclusive use of country-specific sources, allowing for a meaningful comparison of the epidemiological characteristics of B-cell NHL in the 7MM. In addition, this forecast provides detailed segmentation of the B-cell NHL for each country by age, sex, and B-cell NHL subtype, thereby providing a comprehensive view of B-cell NHL in the seven markets. Furthermore, GlobalData epidemiologists constructed and analyzed each B-cell NHL subtype individually, which facilitated an in-depth understanding of B-cell NHL in the 7MM.

Scope

- The Non-Hodgkin’s Lymphoma (NHL) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for NHL in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the incident cases of NHL segmented by sex, age (in five-year increments beginning at 30 years and ending at =85 years), and subtypes in these markets.
- The NHL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The NHL EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global NHL market.
- Quantify patient populations in the global NHL market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for NHL therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 9
3.3 Global Trends 12
3.3.1 US 12
3.3.2 5EU 13
3.3.3 Japan 16
3.4 Forecast Methodology 16
3.4.1 Sources Used 19
3.4.2 Sources Not Used 22
3.4.3 Forecast Assumptions and Methods 23
3.5 Epidemiological Forecast for B-Cell NHL (2014-2024) 27
3.5.1 Follicular Lymphoma 27
3.5.2 Marginal Zone Lymphoma 35
3.5.3 DLBCL 42
3.5.4 Mantle Cell Lymphoma 49
3.6 Discussion 56
3.6.1 Epidemiological Forecast Insight 56
3.6.2 Limitations of the Analysis 56
3.6.3 Strengths of the Analysis 57
4 Appendix 58
4.1 Bibliography 58
4.2 About the Authors 62
4.2.1 Epidemiologists 62
4.2.2 Reviewers 63
4.2.3 Global Director of Therapy Analysis and Epidemiology 64
4.2.4 Global Head of Healthcare 64
4.3 About GlobalData 65
4.4 About EpiCast 65
4.5 Disclaimer 66

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for NHL 11
Table 2: US, Age- and Sex-Specific Incidence of B-Cell NHL during 2001-2010 13
Table 3: 7MM, Sources of B-Cell NHL Incidence Data 18
Table 4: 7MM, Incident Cases of Follicular Lymphoma, Ages ?30 Years, Both Sexes, N, Selected Years 2014-2024 28
Table 5: 7MM, Age-Specific Incident Cases of Follicular Lymphoma, Both Sexes, N (Row %), 2014 30
Table 6: 7MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages ?30 Years, N (Row %), 2014 32
Table 7: 7MM, Incident Cases of Marginal Zone Lymphoma, Ages ?30 Years, Both Sexes, N, Selected Years 2014-2024 35
Table 8: 7MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Both Sexes, N (Row %), 2014 37
Table 9: 7MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages ?30 Years, N (Row %), 2014 39
Table 10: 7MM, Incident Cases of DLBCL, Ages ?30 Years, Both Sexes, N, Selected Years 2014-2024 42
Table 11: 7MM, Age-Specific Incident Cases of DLBCL, Both Sexes, N (Row %), 2014 44
Table 12: 7MM, Sex-Specific Incident Cases of DLBCL, Ages ?30 Years, N (Row %), 2014 46
Table 13: 7MM, Incident Cases of Mantle Cell Lymphoma, Ages ?30 Years, Both Sexes, N, Selected Years 2014-2024 49
Table 14: 7MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N (Row %), 2014 51
Table 15: 7MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages ?30 Years, N (Row %), 2014 53

1.2 List of Figures
Figure 1: 7MM, Incident Cases of Follicular Lymphoma, Ages ?30 Years, Both Sexes, N, 2014-2024 28
Figure 2: 7MM, Age-Specific Incident Cases of Follicular Lymphoma, Ages ?30 Years, Both Sexes, N, 2014 31
Figure 3: 7MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages ?30 Years, N, 2014 33
Figure 4: 7MM, Age-Standardized Incidence of Follicular Lymphoma (Cases per 100,000 Population), Ages ?30 Years, by Sex, 2014 34
Figure 5: 7MM, Incident Cases of Marginal Zone Lymphoma, Ages ?30 Years, Both Sexes, N, 2014-2024 36
Figure 6: 7MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Ages ?30 Years, Both Sexes, N, 2014 38
Figure 7: 7MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages ?30 Years, N, 2014 40
Figure 8: 7MM, Age-Standardized Incidence of Marginal Zone Lymphoma (Cases per 100,000 Population), Ages ?30 Years, by Sex, 2014 41
Figure 9: 7MM, Incident Cases of DLBCL, Ages ?30 Years, Both Sexes, N, 2014-2024 43
Figure 10: 7MM, Age-Specific Incident Cases of DLBCL, Ages ?30 Years, Both Sexes, N, 2014 45
Figure 11: 7MM, Sex-Specific Incident Cases of DLBCL, Ages ?30 Years, N, 2014 47
Figure 12: 7MM, Age-Standardized Incidence of DLBCL (Cases per 100,000 Population), Ages ?30 Years, by Sex, 2014 48
Figure 13: 7MM, Incident Cases of Mantle Cell Lymphoma, Ages ?30 Years, Both Sexes, N, 2014-2024 50
Figure 14: 7MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N, 2014 52
Figure 15: 7MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages ?30 Years, N, 2014 54
Figure 16: 7MM, Age-Standardized Incidence of Mantle Cell Lymphoma (Cases per 100,000 Population), Ages ?30 Years, by Sex, 2014 55

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016-2020 Nucleic Acid Testing: Infectious Diseases, Cancer, Genetic Diseases, Forensic Testing, Paternity Testing/HLA Typing--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence

2016-2020 Nucleic Acid Testing: Infectious Diseases, Cancer, Genetic Diseases, Forensic Testing, Paternity Testing/HLA Typing--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence

  • $ 15 900
  • Industry report
  • March 2016
  • by Venture Planning Group

This unique seven-country, 1,050-page report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the NAT market during this ...

OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2024

OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2024

  • $ 9 495
  • Industry report
  • February 2016
  • by Global Data

OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2024 Summary The head and neck cancer (HNC) market is one currently dominated by generic chemotherapies, ...

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

  • $ 6 995
  • Industry report
  • February 2016
  • by GBI Research

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes Summary The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.